… of a novel therapeutic approach for malignant glioma patients, we conducted the current …
of gefitinib plus sirolimus, an mTOR antagonist, in patients with recurrent malignant glioma. Our …

… in combination with sirolimus among recurrent malignant glioma patients. In that study,
we also confirmed that gefitinib pharmacokinetics are not affected by sirolimus co-administration. …

… have shown antitumor activity in malignant glioma [14, 15]. … sirolimus was to assess the
safety and maximum tolerated dose (MTD) of vandetanib and sirolimus in patients with recurrent …

… target of rapamycin (mTOR) also promotes GBM growth and rapamycin blocks the … combination
of gefitinib (iressa), and sirolimus (rapamycin) should have a synergistic effect in treating …

… Sirolimus and erlotinib … sirolimus in recurrent malignant glioma demonstrated acceptable
toxicity, 26 and a pilot study of gefitinib or erlotinib and sirolimus in heavily pretreated recurrent …

… of erlotinib and sirolimus for the treatments of recurrent malignant gliomas. Patients with … )
grade III glioma and grade IV glioblastoma and radiographically proven tumor recurrence were …

… Selected signaling pathways in malignant gliomas. By … trials for malignant glioma. A
variety of mTOR inhibitors have been evaluated in malignant glioma including rapamycin (sirolimus, …

… AKT activation, which activates mammalian Target of Rapamycin (mTOR). AKT and mTOR
… with a diagnosis of recurrent/progressive GBM or other malignant glioma. Prior radiotherapy …

… most patients with high grade malignant glioma ultimately fail locally or … of salvage strategies
in recurrent high grade glioma. Material and methods: … mammalian target of rapamycin …

… Sirolimus, a macrocyclic lactone and potent … Rapamycin and temsirolimus bind to immunophilin
FKBP-12 to form a complex that interacts with the mammalian target of rapamycin kinase …